PPI Safety Issues

Save

There are more than 11 million proton pump inhibitor (PPI) prescriptions written each year in the United States. While these agents have dramatically changed the management and outcome of upper gastrointestinal (GI) erosive and inflammatory disorders, their use has not been without safety concerns.

Cautious Optimism for Biosimilars in Rheumatology

Save

A Low Risk of Inflammatory Bowel Disease with IL-17 Inhibition

Save

Colitis onset or worsening inflammatory bowel disease has been reported with either of the new IL-17 inhibitors, ixekizumab (IXE) and secukinumab (SEC). Large database studies show these to be rare.

CHMP Recommend Baricitinib for Approval in Europe

Save

Eli Lilly and Company announced last friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib for the treatment of adults with moderate to severely active rheumatoid arthritis (R

A Link Between Periodontal Disease and Rheumatoid Arthritis

Save

Research from Johns Hopkins reports that rheumatoid arthritis (RA) patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to that seen in RA. Results published in Science Translational Medicine showed that Aggregatibacter actinomycetemcomitans can produce hypercitrullination of patient neutrophils, indicating its possible role in triggering RA. (Citation source: http://buff.ly/2hZTBG8)

BEST-D Trial: Higher Doses of Vitamin D may be Required for Optimal Osteoporosis Prevention

Save

Osteoporosis is a major public health problems and is associated with a high burden of fractures and subsequent increased mortality.

Risk of GI Perforations on Biologics

Save

Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.

Osteoporosis 2016 Year in Review - No new drug approvals, and a crisis in care

Save

No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.

RheumNow Week in Review – 16 December 2016

Save

Dr. Jack Cush reviews highlights from this week on RheumNow.com

EULAR 2016 Recommendations on Early Arthritis

Save

Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.

Lupus May Be at Increased Risk for Dementia

Save

Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.

However, dementia is often not reported or studied in cohorts with neurologic disease in lupus. 

Supreme Court Declines Biosimilar Patent Dispute

Save

The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.

Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes

Save

Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients. 

Rituximab May Reduce Mortality Risk in Rheumatoid Lung Disease

Save

While it is known that rheumatoid arthritis (RA) patients with interstitial lung involvement is associated with severe seropositive disease and is associated with an increased mortality.

Nonsignificant CV Risk with Actemra vs Enbrel

Save

WASHINGTON -- Rheumatoid arthritis is a recognized risk factor for heart attacks and stroke, but a study comparing two leading biologics found only a non-significant increase in relative risk for patients treated with toclizimab (Actemra) vs etanercept (Enbrel), researchers reported here.

Physicians Still Over-Prescribe Antibiotics, Narcotics and Opioids

Save

A study by the American College of Physicians (ACP) found that physicians continue to prescribe treatments that offer little benefit to patients, despite the advice of clinical guidelines.

Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study

Save

The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.

Is ABT-494 the Next JAK Inhibitor?

Save

Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.

The RheumNow Week in Review – 2 December 2016

Save

Dr. Cush highlights reports from this week on RheumNow.com.

CURES Act : House Passes Largest Bill Since Obamacare

Save

The 21st Century Cures Act has become one of the most-lobbied health care bills in recent history, with nearly a half billion dollars being spent on both sides - those for and against the bill.